22.16
price down icon1.51%   -0.34
pre-market  Pre-market:  21.65   -0.51   -2.30%
loading
Kiniksa Pharmaceuticals International Plc stock is traded at $22.16, with a volume of 496.63K. It is down -1.51% in the last 24 hours and up +12.77% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
See More
Previous Close:
$22.50
Open:
$22.94
24h Volume:
496.63K
Relative Volume:
1.12
Market Cap:
$1.61B
Revenue:
$384.10M
Net Income/Loss:
$-9.07M
P/E Ratio:
-158.29
EPS:
-0.14
Net Cash Flow:
$11.10M
1W Performance:
+4.18%
1M Performance:
+12.77%
6M Performance:
-12.27%
1Y Performance:
+8.31%
1-Day Range:
Value
$22.12
$22.94
1-Week Range:
Value
$20.39
$22.94
52-Week Range:
Value
$16.56
$28.15

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name
Name
Kiniksa Pharmaceuticals International Plc
Name
Phone
(781) 431-9100
Name
Address
23 OLD BOND STREET, FLOOR 3, LONDON
Name
Employee
315
Name
Twitter
@kiniksa
Name
Next Earnings Date
2024-10-29
Name
Latest SEC Filings
Name
KNSA's Discussions on Twitter

Compare KNSA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
KNSA
Kiniksa Pharmaceuticals International Plc
22.16 1.61B 384.10M -9.07M 11.10M -0.14
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
160.06 71.67B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.03 47.44B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.19 46.08B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.46 18.86B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
131.36 13.97B 612.78M -86.37M -62.91M -0.87

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-13-24 Initiated Jefferies Buy
May-03-24 Initiated Wells Fargo Overweight
Jun-29-20 Reiterated BofA Securities Buy
Apr-01-20 Initiated BofA/Merrill Buy
Mar-11-19 Initiated Barclays Overweight
Dec-12-18 Reiterated Wedbush Outperform
Jun-19-18 Initiated JMP Securities Mkt Outperform
View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

pulisher
05:51 AM

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now - The Motley Fool

05:51 AM
pulisher
Mar 13, 2025

Taking on analysts’ expectations and winning: Kiniksa Pharmaceuticals International Plc (KNSA) - SETE News

Mar 13, 2025
pulisher
Mar 13, 2025

Citigroup Initiates Coverage on Kiniksa Pharmaceuticals International With Buy Rating, $40 Price Target - Marketscreener.com

Mar 13, 2025
pulisher
Mar 12, 2025

Kiniksa Pharmaceuticals COO sells shares worth $261,333 - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Kiniksa Pharmaceuticals COO sells shares worth $261,333 By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 07, 2025

Deeper Dive: Understanding Kiniksa Pharmaceuticals International Plc (KNSA) Through its Various Ratios - The Dwinnex

Mar 07, 2025
pulisher
Mar 06, 2025

Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? - Insider Monkey

Mar 06, 2025
pulisher
Mar 06, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Rhumbline Advisers - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

New York State Common Retirement Fund Has $302,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Sees Large Increase in Short Interest - Defense World

Mar 05, 2025
pulisher
Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey

Mar 02, 2025
pulisher
Mar 02, 2025

Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? - Insider Monkey

Mar 02, 2025
pulisher
Feb 28, 2025

12 Best Small Cap Pharma Stocks to Buy Now - Insider Monkey

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Kiniksa Pharmaceuticals International PLC (KNSA): A Str - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 26, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Q4 2024 Earnings: Revenue at $122.5M, Mi - GuruFocus.com

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

Big Pipeline Updates From Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Seeking Alpha

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Swings to Q4 Loss, Revenue Increases -February 25, 2025 at 08:20 am EST - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa to launch Phase 2/3 trial for heart drug KPL-387 By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Total Revenue $122.5M, vs. FactSet Est of $123.4M - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q4 Net Loss $-0.12 a Share, vs. FactSet Est of $-0.06 Loss - Marketscreener.com

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Reports Strong Q4 2024 Financials with ARCALYST Revenue of $417 Million and Anticipates 2025 Sales Growth - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can Kiniksa's 79% Revenue Surge Continue as Company Shifts Pipeline Focus? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Can Kiniksa's New Pericarditis Drug Build on Its $800M ARCALYST Success? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

KNSAKiniksa Pharmaceuticals International, plc Latest Stock News & Market Updates - StockTitan

Feb 24, 2025
pulisher
Feb 21, 2025

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 - GlobeNewswire

Feb 21, 2025
pulisher
Feb 14, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells $273,980 in shares - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain - Seeking Alpha

Feb 13, 2025
pulisher
Feb 13, 2025

Kiniksa Pharmaceuticals COO sells shares worth $273,980 By Investing.com - Investing.com Canada

Feb 13, 2025
pulisher
Feb 07, 2025

Kiniksa Pharmaceuticals International Plc (KNSA) Stock: Tracking the Weekly Performance - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Is Kiniksa Pharmaceuticals International Plc (KNSA) a opportunity to investors? - US Post News

Feb 06, 2025
pulisher
Feb 05, 2025

Keeping an Eye on Kiniksa Pharmaceuticals International Plc (KNSA) After Insider Trading Activity - Knox Daily

Feb 05, 2025
pulisher
Feb 04, 2025

Stock Market Recap: Kiniksa Pharmaceuticals International Plc (KNSA) Concludes at 18.88, a -3.67 Surge/Decline - The Dwinnex

Feb 04, 2025
pulisher
Jan 28, 2025

Exploring High Growth Tech Stocks in the United States - Simply Wall St

Jan 28, 2025
pulisher
Jan 20, 2025

Kiniksa Pharmaceuticals Reports Strong 2024 Financial Results and Provides 2025 Revenue Guidance - Defense World

Jan 20, 2025
pulisher
Jan 16, 2025

Kiniksa Pharmaceuticals COO Tessari Eben sells shares worth $255,413 - Investing.com India

Jan 16, 2025
pulisher
Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance - The Manila Times

Jan 13, 2025
pulisher
Jan 13, 2025

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net - GlobeNewswire

Jan 13, 2025
pulisher
Jan 13, 2025

Kiniksa's ARCALYST Soars 79% to $416M in 2024, Projects Strong 2025 Growth to $580M - StockTitan

Jan 13, 2025
pulisher
Jan 06, 2025

Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Jan 06, 2025

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$10.31
price down icon 0.77%
$33.62
price up icon 0.63%
$99.29
price down icon 1.55%
$8.98
price down icon 2.81%
$108.99
price down icon 0.07%
$131.36
price up icon 0.08%
Cap:     |  Volume (24h):